Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma

Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma

Source: 
Pharmaceutical Business Review
snippet: 

Exelixis, Inc. today announced that it is initiating COSMIC-313, a phase 3 pivotal trial of cabozantinib (CABOMETYX) in combination with nivolumab (Opdivo) and ipilimumab (Yervoy) versus nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium.